APP and Alzheimer disease: In vitro and in vivo studies on genetic models of AD demonstrate a role of APP or Aβ in impairment of mitochondria, opening up the possibility of multi-targeted treatments aimed at both optimizing bioenergetics and reducing amyloidogenesis.